VYCO · Vycor Medical Inc
$0.04
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred losses since its inception, including a net loss of $2,180 for the six months ended June 30, 2026 and has not generated sufficient positive cash flows from operations. As of June 30, 2026 the Company had a working capital deficiency of $4,294,543 which includes related party liabilities of $3,800,538. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.24M
Shares
33.37M
Volume · Oct 20
63.8K
Avg daily vol (8 sessions)
57.26K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.04
Open$0.05
Day$0.03–0.05
52W close$0.04–0.20
Avg vol 30d30K
Short int12K · 0.0% float
Short vol38%
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.81M
Trailing 12 months
Net income (TTM)
−$59,930
Trailing 12 months
Revenue growth YoY
-15.7%
Year over year
Operating margin
2.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-13.7%
Year over year · fewer shares
Price change (1Y)
-48.1%
Trailing year
Short interest
0.0%
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−63%
below
Price vs 50-day avg
−54%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−45%
trailing
6-month return
−49%
trailing
YTD return
−69%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.04% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Squeeze score
20
low risk · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
Gross margin
113%
expanding
EPS growth
0%
Y/Y
Free cash flow
$-18.7K
Balance sheet
$198.2K
net debt
Quant / Vol
risk profile
Volatility
255%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
46.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−63%
Bearish
Price vs 50-day avg
−54%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.04% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -63%
vs 50-day avg -54%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Cash Operating Expenses non-GAAP | $636,858 | Six months ended June 30, 2026 | — |
| Non-GAAP Operating Profit non-GAAP | $82,740 | Six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VYCO
this stock
Vycor Medical Inc
|
$2.24M | -68.6% | -4.7% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$121.04B | -1.5% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VYCO | -30.9% | -44.9% | -49.3% | -43.3% | -68.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -29.8% | -44.4% | -57.4% | -44.1% | -81.4% |